問卷

TPIDB > Search Result

Search Result

篩選

List

201Cases

2020-09-15 - 2025-10-08

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting6Sites

2020-10-15 - 2027-09-01

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Recruiting13Sites

2020-12-01 - 2028-12-31

Phase I

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2020-12-01 - 2024-01-30

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting5Sites

2021-01-01 - 2024-12-31

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting6Sites

Terminated1Sites

2021-03-31 - 2025-01-31

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites

2021-05-18 - 2023-12-31

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting5Sites

Terminated5Sites

2022-02-01 - 2029-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting9Sites

2022-04-01 - 2024-03-25

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2026-06-01 - 2030-06-30

Phase III

Not yet recruiting
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF)
  • Condition/Disease

    Sacroiliac Joint Pain

  • Test Drug

    Dapagliflozin Elecoglipron

Participate Sites
14Sites

Recruiting14Sites